A Food-Effect Study of E7386 in Healthy Participants

Phase 1

Completed

• Conditions: Food Effect in Healthy Participants
• Interventions: Drug: E7386

• Registration Number: NCT03996226
• Lead Sponsor: Eisai Inc.

Brief Summary

The primary objective of this study is to determine the effect of food in healthy participants on the bioavailability of E7386 following single dose administration with and without a meal.

Detailed Description

Not available

Study Timeline

• Status Verified: 2019-06
• Study Start: 2019-06-07
• Study First Submitted: 2019-06-21
• Study First Submitted QC: 2019-06-21
• Study First Posted: 2019-06-24
• Primary Completion: 2019-10-29
• Study Completion: 2019-10-29
• Last Update Submitted: 2019-11-13
• Last Update Posted: 2019-11-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 17

Inclusion Criteria

1. Non-smoking, healthy participants at the time of informed consent.
2. Body Mass Index (BMI) greater than (>) 18 and less than or equal to (<=) 30 kilogram per square meter (kg/m^2) at Screening.

Exclusion Criteria

1. Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta-human chorionic gonadotropin [ß-hCG] (or human chorionic gonadotropin [hCG]) test with a minimum sensitivity of 25 international units per litre (IU/L) or equivalent units of ß-hCG [or hCG]). A separate baseline assessment is required if a negative screening pregnancy test was obtained more than 72 hours before the first dose of study drug

2. Females of childbearing potential who:

   • Within 28 days before study entry, did not use a highly effective method of contraception, which includes any of the following:

     1. total abstinence (if it is their preferred and usual lifestyle)
     2. an intrauterine device or intrauterine hormone-releasing system
     3. a contraceptive implant
     4. an oral contraceptive (with additional barrier method) (Participant must be on a stable dose of the same oral contraceptive product for at least 28 days before dosing and throughout the study and for 28 days after study drug discontinuation)
     5. have a vasectomized partner with confirmed azoospermia

   • Do not agree to use a highly effective method of contraception (as described above) throughout the entire study period and for 28 days after study drug discontinuation NOTE: All females will be considered to be of childbearing potential unless they are postmenopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group, and without other known or suspected cause) or have been sterilized surgically (i.e., bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before dosing)

3. Males who have not had a successful vasectomy (confirmed azoospermia) and their female partners meet the exclusion criteria No: 2, above. If the female partner is pregnant, then males who do not agree to use Barrier contraception (latex or synthetic condoms) throughout the study period and for 90 days after study drug discontinuation. No sperm donation is allowed during the study period and for 90 days after study drug discontinuation

4. Clinically significant illness that requires medical treatment within 8 weeks or a clinically significant infection that requires medical treatment within 4 weeks of dosing

5. Evidence of disease that may influence the outcome of the study within 4 weeks before dosing; eg, psychiatric disorders and disorders of the gastrointestinal tract, liver, kidney, respiratory system, endocrine system, hematological system, neurological system, or cardiovascular system, or participants who have a congenital abnormality in metabolism

6. Any history of major surgery, e.g., intestinal resections, hepatectomy, nephrectomy, digestive organ resection that may affect absorption, metabolism or excretion of E7386.

7. Any clinically abnormal symptom or organ impairment found by medical history at Screening, and physical examinations, vital signs, electrocardiogram (ECG) finding, or laboratory test results that require medical treatment at Screening

8. Clinically significant ECG abnormality including a marked baseline prolongation of QT/corrected QT interval (QTc) (example: repeated demonstration of a QTc interval greater than (>) 500 milliseconds [msec]), or a family history of prolonged QTc syndrome or sudden death

9. History of drug or alcohol misuse within 6 months prior to Screening, or who had a positive urine drug test at Screening or Baseline

10. Diagnosed with acquired immune deficiency syndrome, or test positive for human immunodeficiency virus (HIV) at screening

11. Active viral hepatitis (A, B or C) as demonstrated by positive serology at Screening

12. Use of prescription drugs within 4 weeks prior to dosing

13. Intake of over-the-counter medications within 2 weeks prior to dosing

14. Intake of caffeinated beverages or food within 72 hours prior to dosing

15. Receipt of blood products within 4 weeks, or donation of blood within 8 weeks, or donation of plasma within 1 week of dosing

16. Participated in another clinical trial less than 4 weeks prior to dosing or was currently enrolled in another clinical trial

17. Consumed grapefruit, starfruit, Seville oranges or their products within 7 days prior to dosing

18. Consumed herbal preparations/medications including but not limited to: St. John's wort, kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone, yohimbe, saw palmetto, and ginseng within 7 days prior to dosing

19. Allergic to E7386 or any of the tablet's ingredients

20. Known history of clinically significant drug or food allergies, or presently experiencing significant seasonal or perennial allergy at Screening.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
E7386: Fed + Fast	E7386	Participants will receive a single oral dose of E7386 tablet in fed condition on Day 1 of treatment period 1 followed by a single oral dose of E7386 tablet in fasted condition on Day 8 of treatment period 2. A washout period of 7 days will be maintained between the 2 treatment periods.
E7386: Fast + Fed	E7386	Participants will receive a single oral dose of E7386 tablet in fasted condition on Day 1 of treatment period 1 followed by a single oral dose of E7386 tablet in fed condition on Day 8 of treatment period 2. A washout period of 7 days will be maintained between the 2 treatment periods.

Primary Outcome Measures

Name	Time	Method
AUC0-t: AUC 0-t: Area Under the Concentration-time Curve From Zero (Pre-dose) to Time of Last Quantifiable Concentration for E7386	Day 1: 0-48 hours; Day 8: 0-48 hours
Cmax: Maximum Observed Plasma Concentration for E7386	Day 1: 0-48 hours; Day 8: 0-48 hours
Tmax: Time to Reach the Maximum Observed Plasma Concentration (Cmax) for E7386	Day 1: 0-48 hours; Day 8: 0-48 hours
AUC0-inf: Area Under the Plasma Concentration-time Curve from Time 0 to Infinite Time for E7386	Day 1: 0-48 hours; Day 8: 0-48 hours

Trial Locations

Locations (1)

PPD; 🇺🇸 Austin, Texas, United States